CERo Therapeutics Holdings, Inc.
CERO
$0.09
$0.0113.64%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.18% | 21.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.47% | 6.35% | |||
| Operating Income | 10.47% | -6.35% | |||
| Income Before Tax | 10.35% | -6.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.35% | -6.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.35% | -6.10% | |||
| EBIT | 10.47% | -6.35% | |||
| EBITDA | 10.60% | -6.58% | |||
| EPS Basic | 85.26% | -84.66% | |||
| Normalized Basic EPS | 65.41% | 64.52% | |||
| EPS Diluted | 85.26% | -84.66% | |||
| Normalized Diluted EPS | 65.41% | 64.52% | |||
| Average Basic Shares Outstanding | 159.15% | -86.44% | |||
| Average Diluted Shares Outstanding | 159.15% | -86.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||